ReviewPharmaceutics2025
Plant Resin Delivery by Nanovectors as an Emerging Approach to Boost Solubility, Permeability and Bioavailability.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advances in Drug Delivery Systems for Boswellic Acids fromInternational journal of molecular sciences · 2026Review
- Chitosan from shrimp shell waste as a carrier for frankincense nanoparticles with enhanced antimicrobial activity.Scientific reports · 2026Article
- Insecticidal Potential ofPlants (Basel, Switzerland) · 2025Article
- From bench to bedside, boswellic acids in anti-inflammatory therapy - mechanistic insights, bioavailability challenges, and optimization approaches.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Resins are complex mixtures of natural constituents containing non-volatile and volatile terpenes, in combination with gums and polyphenols, used since ancient times for their medicinal properties. Current research has evidenced their therapeutic value with a plethora of activities. The main limits of resins and their constituents for their clinical use are low water solubility, poor stability and bioavailability. Therefore, nanovectors including vesicles, solid lipid nanoparticles, micelles, nanoemulsions, microemulsions and mesoporic nanoparticles have been investigated to optimize the biopharmaceutical properties after topical or oral administration of resins or fractions from them, including essential oils or single constituents. In this review, we report the results evidencing that developed nanovectors were able to entrap high amounts of resins or their components, modify the release properties, enhance their cellular uptake and penetration across biological barriers and optimize the biopharmaceutical properties. In addition, the resins or their fractions as enhancer penetration molecules can optimize the architecture and properties of nanovectors in their capacity to circumvent biological barriers. Although no clinical studies have been reported until now, nanovectors represent a huge platform for upgrading therapies and emerging new treatments of resins such as wound healing therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.